Section 232 tariffs on patented pharmaceutical products and associated pharmaceutical ingredients took effect Sept. 29 for companies not covered by the earlier July 31 implementation date. The tariffs follow a Commerce Department investigation that found U.S. dependence on imported pharmaceuticals and pharmaceutical ingredients threatened to impair national security.
Here are four things to know:
- Large manufacturers named in Annex III of Presidential Proclamation 11020 fell under the tariff framework starting July 31, ahead of all other companies, which became subject to it Sept. 29.
- Companies with qualifying most-favored-nation pricing and onshoring agreements with the administration receive a zero tariff rate through Jan. 20, 2029. As of an Aug. 31 White House announcement, all 17 Annex III companies, including AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer and Sanofi, have signed MFN deals, meaning none currently pay the tariff.
- The baseline tariff on covered patented pharmaceuticals and associated ingredients is 100%. Companies with approved U.S. onshoring plans can receive a 20% rate, which is set to increase to 100% April 2, 2030. Different rates apply to products from certain U.S. trading partners, and generic drugs and biosimilars are not subject to the Section 232 pharmaceutical tariffs at this time.
- Health system pharmacy leaders have been watching the tariff timeline closely amid broader efforts to diversify drug sourcing. Vizient projects pharmaceutical prices will rise 3.54% in 2027, a forecast that does not include potential tariff effects because of uncertainty surrounding their implementation and impact.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
